Skip to main content
. 2023 Apr 10;43(6):1259–1271. doi: 10.1007/s10875-023-01470-2

Fig. 2.

Fig. 2

fSCIG dose, infusion volume, and rate in the total population over 36 months of follow-up. n values represent number of patients at each visit; n values for each parameter may differ slightly due to missing data for that individual parameter. fSCIG, facilitated subcutaneous immunoglobulin